These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15570926)

  • 21. [Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].
    Yajima T; Furukawa Y; Ishii Y; Hattori Y; Matsumoto N; Yamamoto M; Yamaoka Y; Fujihara M; Fujita M; Kuniki H
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):953-7. PubMed ID: 15222120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
    Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA
    Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.
    Hirao K; Kawamoto H; Sakakihara I; Noma Y; Yamamoto N; Harada R; Tsutsumi K; Fujii M; Kato H; Kurihara N; Mizuno O; Ogawa T; Ishida E; Yamamoto K
    Int J Clin Oncol; 2011 Dec; 16(6):637-45. PubMed ID: 21519814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of gemcitabine in patients with advanced pancreatic cancer.
    Carmichael J; Fink U; Russell RC; Spittle MF; Harris AL; Spiessi G; Blatter J
    Br J Cancer; 1996 Jan; 73(1):101-5. PubMed ID: 8554969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of unresectable advanced pancreatic tail cancer successfully treated with gemcitabine hydrochloride].
    Akutsu Y; Endo M; Yoshinaga Y; Hoshino T; Ota Y; Tsunoda Y; Matsubara H; Ochiai T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):243-5. PubMed ID: 15751642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer.
    Rezaee M; Wang J; Razavi M; Ren G; Zheng F; Hussein A; Ullah M; Thakor AS
    Sci Rep; 2019 Nov; 9(1):15929. PubMed ID: 31685925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
    Takamori H; Kanemitsu K; Tsuji T; Tanaka H; Chikamoto A; Nakahara O; Hiraoka T; Ikeda O; Kudo K; Imuta M; Yamashita Y
    Pancreas; 2005 Apr; 30(3):223-6. PubMed ID: 15782098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
    Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
    J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
    Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
    J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
    Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of gemcitabine in patients with advanced pancreatic cancer.
    Okada S; Ueno H; Okusaka T; Ikeda M; Furuse J; Maru Y
    Jpn J Clin Oncol; 2001 Jan; 31(1):7-12. PubMed ID: 11256843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
    Brand R; Capadano M; Tempero M
    Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
    Wada K; Sano K; Amano H; Miura F; Toyota N; Ito H; Shibuya M; Ikeda Y; Kainuma M; Takada T
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):692-8. PubMed ID: 26136371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Gemcitabine: Applications and perspectives].
    Tumori; 1997; 83(5):877-80. PubMed ID: 9446252
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
    Furuse J; Ishii H; Okusaka T; Nagase M; Nakachi K; Ueno H; Ikeda M; Morizane C; Yoshino M
    Jpn J Clin Oncol; 2005 Dec; 35(12):733-8. PubMed ID: 16303793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
    Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
    Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.
    Nakai Y; Isayama H; Kawabe T; Tsujino T; Yoshida H; Sasaki T; Tada M; Arizumi T; Yagioka H; Kogure H; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Omata M
    Pancreas; 2008 Nov; 37(4):405-10. PubMed ID: 18953253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
    Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of unresectable pancreatic cancer showing tumor dormancy treated with gemcitabine].
    Egawa T; Nagashima A; Kitano M; Doi M; Hayashi S; Yoshii H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1932-4. PubMed ID: 15553764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.